CEO Gary Phillips said, “We are confident that these results, if repeated in the whole study population, will satisfy regulatory requirements to continue the development of PXS-5505 in myelofibrosis and also excite clinicians, patients and industry groups who are closely following our progress with this novel mechanism." …
Pharmaxis reports positive interim data from myelofibrosis study
October 20, 2022 BioPharmaAustralian Biotech
Latest Video
New Stories
-
Nyrada commences recruitment for phase one clinical trial
March 17, 2025 - -
Neurizon Therapeutics updates investors on initiatives to lift clinical hold
March 17, 2025 - - Australian Biotech -
Radiopharm Theranostics says new data confirms positive tumour uptake
March 17, 2025 - - Australian Biotech -
Race secures ethics approval for RC220 Phase 1 solid tumour trial
March 17, 2025 - - Australian Biotech -
TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer
March 17, 2025 - - Latest News -
Doctor group changes position on weight-loss therapies and the PBS
March 17, 2025 - - Latest News -
In 2025, the US is more likely to adopt PBS pricing policies than oppose them
March 17, 2025 - - Latest News